HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Combination of platelet count and neutrophil to lymphocyte ratio is a useful predictor of postoperative survival in patients undergoing surgery for gastric cancer.

AbstractOBJECTIVE:
To investigate the clinical utility of the Combination of Platelet count and Neutrophil to Lymphocyte Ratio (COP-NLR) for predicting the postoperative survival of patients undergoing surgery for gastric cancer (GC).
METHODS:
The COP-NLR was calculated on the basis of data obtained on the day of admission as follows: patients with both an elevated platelet count (>300 × 10(3) /µl) and an elevated NLR (>3) were allocated a score of 2, and patients showing one or neither were allocated a score of 1 or 0, respectively. Five hundred forty-four patients for whom data were sufficient to allow analysis of the relationship between clinicolaboratory characteristics and postoperative survival were enrolled.
RESULTS:
Multivariate analysis using the 12 clinical characteristics selected by univariate analyses revealed that the COP-NLR was associated with OS (hazard ratio, 1.781; 95% C.I., 1.094-2.899; P = 0.020) along with age, tumor type, lymph node metastasis and albumin level. Kaplan-Meier analysis and log rank test demonstrated significant differences in both OS and cancer-specific survival among patients with COP-NLR 0, 1, and 2 (P < 0.001).
CONCLUSION:
The COP-NLR is able to predict postoperative survival of patients with GC and classify such patients into three independent groups before surgery.
AuthorsMitsuru Ishizuka, Yusuke Oyama, Akihito Abe, Keiichi Kubota
JournalJournal of surgical oncology (J Surg Oncol) Vol. 110 Issue 8 Pg. 935-41 (Dec 2014) ISSN: 1096-9098 [Electronic] United States
PMID25146385 (Publication Type: Journal Article)
Copyright© 2014 Wiley Periodicals, Inc.
Topics
  • Aged
  • Female
  • Humans
  • Lymphocytes
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Neutrophils
  • Platelet Count
  • Stomach Neoplasms (blood, mortality, pathology, surgery)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: